by Rod Raynovich | Apr 28, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Earnings season for diagnostics and tools companies begins today with GenProbe (GPRO $79.39) after the market close. But the stock is up 13% today on a Bloomberg scoop that the Company has hired Morgan Stanley as an investment banker to seek a buyer. The market cap is...
by Rod Raynovich | Apr 27, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The biotech bulls are in charge this week. The sellers must have been watching the Bernanke Press Conference today or maybe buying gold as biotech stocks had one of their best days of the year. The bellwether ETF IBB was up 2.37% to $108.71 an all time high exceeding...
by Rod Raynovich | Apr 26, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Vertex (VRTX $54.17) soared 12.75% today on expectations for FDA approval of it telaprevir HCV drug Thursday April 28. Today FDA staff in a preliminary review commented that the Vertex drug when combined with current therapies is more effective than those drugs alone....
by Rod Raynovich | Apr 25, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Caution is still on as we have had big moves YTD and speculative stocks are selling off. High flyers Amarin (AMRN $16.10) is down 4.85% on volume of 6.85M shares while Ariad (ARIA $8.14) was down 3.2% on volume of 1.5M shares.. Vertex(VRTX $48.04) down 2.69%...
by Rod Raynovich | Apr 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biogen(BIIB $103) soared 19% today reporting profit of $294.3M EPS of $1.20 compared to $217.4 and EPS of 0.80 in the previous year. Revenue from its drug Tysabri used to treat Crohn’s and MS grew 15% to $251M. The Company also reported late stage clinical...
by Rod Raynovich | Apr 20, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Tech Goes from Laggard to Leader Taking Strong Biotech Sector Along for the Ride Tech stocks rallied big today with the NASDAQ up 2.1% to 2802, The Dow hit a new 2 1/2 year high up 1.5% to 12,453.The main catalyst was Intel (INTC $21.41) up 7.4% beating EPS estimates...
by Rod Raynovich | Apr 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Markets stabilized today with major indices up in the 0.4% range. Despite some weakness in meteoric biopharma stocks the healthcare sector is catching bids. Unloved and unwanted Johnson and Johnson(JNJ $61.87) is trying to shake off product quality issues up 2.33%,...
by Rod Raynovich | Apr 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Even the biotech bulls bailed today on the double whammy of concern about Europe’s debt crisis and the S&P echoing the Tea Party refrain about the U.S. budget deficit and need for fiscal reform. As of mid-day trading both the S&P 500 and the NASDAQ is...
by Rod Raynovich | Apr 15, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Drug and Biotechnology Stocks Up Across the Spectrum Its “groundhog day” in biotech world. Apparently money that has come out of tech stocks and money markets is going into healthcare stocks. In case you missed it even large cap drug stocks which have...
by Rod Raynovich | Apr 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotech stocks are up again today ignoring the overall weakness in tech stocks. Among the notable movers today are: Dendreon (DNDN $41.15) broke out above 40 up 5.5% on heavy volume with high expectations for the May 2 Conference call and presentation of data at ASCO...
